Q2 Earnings Forecast for Sage Therapeutics Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at Wedbush lifted their Q2 2025 EPS estimates for Sage Therapeutics in a research report issued on Tuesday, April 29th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($0.97) per share for the quarter, up from their prior forecast of ($1.02). Wedbush currently has a "Neutral" rating and a $6.00 price target on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics' Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.72) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($0.73) EPS.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same period last year, the firm earned ($1.80) earnings per share. The firm's revenue for the quarter was up 78.0% on a year-over-year basis.

Several other research firms have also weighed in on SAGE. Scotiabank reduced their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, February 12th. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Bank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price objective for the company. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Finally, Canaccord Genuity Group lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $8.81.

Sage Therapeutics Price Performance

Shares of Sage Therapeutics stock traded up $0.03 during trading on Friday, hitting $6.89. 197,602 shares of the company were exchanged, compared to its average volume of 1,219,270. The firm has a market capitalization of $431.15 million, a P/E ratio of -1.05 and a beta of 0.20. The firm's fifty day moving average price is $7.54 and its 200 day moving average price is $6.77. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $13.47.

Institutional Trading of Sage Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Picton Mahoney Asset Management increased its position in shares of Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 3,581 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Sage Therapeutics in the fourth quarter valued at $49,000. Ieq Capital LLC acquired a new position in Sage Therapeutics during the fourth quarter worth $57,000. GAMMA Investing LLC raised its position in Sage Therapeutics by 16,118.0% during the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 8,059 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after acquiring an additional 2,268 shares during the last quarter. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.